Wall Street brokerages forecast that BioLife Solutions Inc (NASDAQ:BLFS) will post earnings per share of $0.04 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for BioLife Solutions’ earnings, with the highest EPS estimate coming in at $0.06 and the lowest estimate coming in at $0.02. BioLife Solutions reported earnings per share of ($0.03) in the same quarter last year, which would indicate a positive year over year growth rate of 233.3%. The company is expected to announce its next quarterly earnings report on Thursday, November 8th.

According to Zacks, analysts expect that BioLife Solutions will report full-year earnings of $0.15 per share for the current year, with EPS estimates ranging from $0.13 to $0.17. For the next year, analysts expect that the business will post earnings of $0.30 per share, with EPS estimates ranging from $0.23 to $0.41. Zacks’ earnings per share averages are an average based on a survey of research firms that follow BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 9th. The medical equipment provider reported $0.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.01. BioLife Solutions had a return on equity of 2.24% and a net margin of 1.76%. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $5.20 million.

BLFS has been the subject of a number of recent analyst reports. Northland Securities reiterated a “buy” rating and set a $18.00 price target on shares of BioLife Solutions in a report on Friday, August 10th. B. Riley set a $23.00 price target on BioLife Solutions and gave the stock a “buy” rating in a report on Tuesday, August 14th. Maxim Group reiterated a “buy” rating and set a $26.00 price target on shares of BioLife Solutions in a report on Wednesday, September 5th. BidaskClub downgraded BioLife Solutions from a “strong-buy” rating to a “buy” rating in a report on Friday, September 7th. Finally, TheStreet upgraded BioLife Solutions from a “d” rating to a “c-” rating in a report on Tuesday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. BioLife Solutions presently has a consensus rating of “Buy” and a consensus price target of $22.33.

BioLife Solutions stock traded down $0.04 during trading hours on Friday, reaching $19.04. 1,407 shares of the company’s stock were exchanged, compared to its average volume of 407,602. BioLife Solutions has a twelve month low of $4.56 and a twelve month high of $26.35. The company has a market cap of $322.32 million, a P/E ratio of -93.05 and a beta of 1.46.

In other BioLife Solutions news, CFO Greef Roderick De sold 10,000 shares of BioLife Solutions stock in a transaction dated Wednesday, July 18th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer now owns 24,583 shares in the company, valued at approximately $491,660. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Walter Villiger sold 214,286 shares of BioLife Solutions stock in a transaction dated Monday, July 9th. The shares were sold at an average price of $11.37, for a total value of $2,436,431.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 594,925 shares of company stock valued at $7,559,453. Company insiders own 38.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Shepherd Kaplan Krochuk LLC acquired a new position in BioLife Solutions during the 2nd quarter valued at about $183,000. BNP Paribas Arbitrage SA acquired a new position in BioLife Solutions during the 2nd quarter valued at about $799,000. Perkins Capital Management Inc. boosted its stake in BioLife Solutions by 473.8% during the 2nd quarter. Perkins Capital Management Inc. now owns 157,800 shares of the medical equipment provider’s stock valued at $1,800,000 after purchasing an additional 130,300 shares during the last quarter. EAM Global Investors LLC acquired a new position in BioLife Solutions during the 2nd quarter valued at about $1,294,000. Finally, Bank of Montreal Can acquired a new position in BioLife Solutions during the 2nd quarter valued at about $114,000. Institutional investors and hedge funds own 27.77% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Read More: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.